Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma

Objectives Radiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA...

Full description

Saved in:
Bibliographic Details
Published inEuropean radiology Vol. 31; no. 11; pp. 8649 - 8661
Main Authors Lin, Chen-Chun, Lui, Kar-Wai, Chen, Wei-Ting, Hsieh, Yi-Chung, Cheng, Ya-Ting, Teng, Wei, Lin, Shi-Ming
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2021
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0938-7994
1432-1084
1432-1084
DOI10.1007/s00330-021-07729-9

Cover

Abstract Objectives Radiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA). Methods We retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison. Results SW-RFA showed a higher rate of achieving an adequate safety margin ( p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates ( p < 0.001) and better overall survival ( p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030–0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152–0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate ( p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C ( p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000). Conclusions The switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival. Key Points • Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma. • Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC. • Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation.
AbstractList ObjectivesRadiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA).MethodsWe retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison.ResultsSW-RFA showed a higher rate of achieving an adequate safety margin (p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates (p < 0.001) and better overall survival (p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030–0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152–0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate (p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C (p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000).ConclusionsThe switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival.Key Points• Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma.• Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC.• Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation.
Objectives Radiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA). Methods We retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison. Results SW-RFA showed a higher rate of achieving an adequate safety margin ( p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates ( p < 0.001) and better overall survival ( p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030–0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152–0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate ( p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C ( p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000). Conclusions The switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival. Key Points • Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma. • Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC. • Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation.
Radiofrequency ablation (RFA) of medium-sized (3-5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA).OBJECTIVESRadiofrequency ablation (RFA) of medium-sized (3-5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA).We retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison.METHODSWe retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison.SW-RFA showed a higher rate of achieving an adequate safety margin (p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates (p < 0.001) and better overall survival (p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030-0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152-0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate (p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C (p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000).RESULTSSW-RFA showed a higher rate of achieving an adequate safety margin (p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates (p < 0.001) and better overall survival (p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030-0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152-0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate (p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C (p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000).The switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival.CONCLUSIONSThe switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival.• Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma. • Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC. • Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation.KEY POINTS• Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma. • Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC. • Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation.
Radiofrequency ablation (RFA) of medium-sized (3-5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative volume to better cover larger tumors. This study aims to compare the long-term outcomes of medium-sized HCC treated by either SW-RFA or single-monopolar RFA (S-RFA). We retrospectively reviewed 139 cases (147 medium-size HCC) between 2008 and 2014. Under propensity score matching, a total of 43 paired patients with medium-size HCC and balanced clinical variables treated by either SW-RFA or S-RFA were selected for comparison. SW-RFA showed a higher rate of achieving an adequate safety margin (p = 0.002). After a mean follow-up period of 40.4 months, SW-RFA produced significantly lower global RFA failure rates (p < 0.001) and better overall survival (p = 0.005) compared to S-RFA. SW-RFA was independently associated with a decreased risk of global RFA failure (hazard ratio [HR]: 0.136, 95% confidence interval [CI]: 0.030-0.607, p = 0.009) and improved overall survival (HR: 0.337, 95% CI: 0.152-0.747, p = 0.007). By last follow-up, the SW-RFA group maintained a superior tumor-free rate (p = 0.010) and fewer progressions to Barcelona Clinic Liver Cancer stage C (p = 0.011). Major complication rates were comparable in both groups (SW-RFA: 2.3% vs. S-RFA: 4.7%, p = 1.000). The switching multi-monopolar ablation technique could be beneficial for patients with medium-sized HCCs given sustained control of larger tumors with better overall survival. • Switching monopolar ablation could provide a sustained local tumor control and better overall survival than single-monopolar ablation for the medium-sized hepatocellular carcinoma. • Compared to single-monopolar ablation, switching monopolar ablation could create a larger homogeneous coagulation volume by using a shorter total ablation time to achieve a higher rate of adequate safety margin for a medium-sized HCC. • Patients with medium-sized HCC can be maintained at a higher rate of tumor-free status and at a lower risk of progression into BCLC stage C in the follow-up period after ablation by switching monopolar than by single-monopolar ablation.
Author Hsieh, Yi-Chung
Lin, Chen-Chun
Lin, Shi-Ming
Lui, Kar-Wai
Teng, Wei
Chen, Wei-Ting
Cheng, Ya-Ting
Author_xml – sequence: 1
  givenname: Chen-Chun
  surname: Lin
  fullname: Lin, Chen-Chun
  organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University
– sequence: 2
  givenname: Kar-Wai
  surname: Lui
  fullname: Lui, Kar-Wai
  organization: Department of Medical Imaging & Intervention, Linkou Chang Gung Memorial Hospital, Chang Gung University
– sequence: 3
  givenname: Wei-Ting
  surname: Chen
  fullname: Chen, Wei-Ting
  organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University
– sequence: 4
  givenname: Yi-Chung
  surname: Hsieh
  fullname: Hsieh, Yi-Chung
  organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University
– sequence: 5
  givenname: Ya-Ting
  surname: Cheng
  fullname: Cheng, Ya-Ting
  organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University
– sequence: 6
  givenname: Wei
  surname: Teng
  fullname: Teng, Wei
  organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University
– sequence: 7
  givenname: Shi-Ming
  orcidid: 0000-0001-7527-6181
  surname: Lin
  fullname: Lin, Shi-Ming
  email: lsmpaicyto@cloud.cgmh.org.tw, lsmpaicyto@gmail.com
  organization: Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33895858$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1rFTEYhYNU7G31D7iQATduom8-5iZZSvELCi7Udcgk79ymzCTXZMZSf725vS1CF10FwnMO57znjJyknJCQ1wzeMwD1oQIIARQ4o6AUN9Q8IxsmBacMtDwhGzBCU2WMPCVntV4DgGFSvSCnQmjT615vyP7HTVz8VUy7bs4p7_PkSldciHks-HvF5G87N0xuiTl1cd6X_AdrN-W0owuWucvr4vPcvvLYzRjiOtMa_2LornDvluxxmtaDpXfFx5Rn95I8H91U8dX9e05-ff708-Irvfz-5dvFx0vqheoXKgYMiP1WmV5uWZA-SI2coe9hGIPiXDoIAmDotfNuy3gQrQ_rQeLWKx_EOXl39G2RW4-62DnWQxyXMK_V8p5pJRkX0NC3j9DrvJbU0jVKc224EbxRb-6pdWhN7b7E2ZVb-3DLBugj4EuuteBofVzuDrcUFyfLwB5ms8fZbJvN3s1mTZPyR9IH9ydF4iiqDU47LP9jP6H6B_0vq8w
CitedBy_id crossref_primary_10_2147_JHC_S268300
crossref_primary_10_1111_liv_15052
Cites_doi 10.1371/journal.pone.0161980
10.1148/radiol.13130940
10.1148/radiol.2411051271
10.1016/j.jvir.2011.02.005
10.1159/000343877
10.1097/01.sla.0000201480.65519.b8
10.1016/j.jvir.2014.08.027
10.1016/S2468-1253(18)30029-3
10.1002/hep.20933
10.1097/RLI.0b013e3180661aad
10.1007/s00270-012-0377-1
10.1016/j.jvir.2016.02.031
10.1016/j.jvir.2007.05.010
10.3748/wjg.v21.i10.2997
10.1007/s00330-019-06575-0
10.1016/j.jhep.2012.09.020
10.1148/radiol.14132958
10.1002/hep.21164
10.1200/JCO.2012.42.9936
10.1016/j.jvir.2008.09.021
10.2214/AJR.04.1346
10.21037/jgo.2019.01.34
10.1159/000367755
10.1038/ajg.2011.425
10.1016/j.jvir.2009.09.003
10.1080/02656736.2018.1440017
10.1002/cncr.25314
10.1016/j.jhep.2016.07.010
10.1148/radiol.2442060826
10.3348/kjr.2012.13.1.34
10.1245/s10434-011-1673-8
10.1148/radiol.13121736
10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
10.1016/j.ejrad.2013.12.015
10.1002/hep.29913
10.1016/j.suronc.2007.08.002
10.1007/s12072-017-9799-9
10.1097/SLA.0000000000001797
10.1016/j.jhep.2018.02.026
10.1016/j.jhep.2017.10.004
10.1016/j.hpb.2020.01.008
10.1016/j.jhep.2018.03.019
ContentType Journal Article
Copyright European Society of Radiology 2021
European Society of Radiology 2021.
2021. European Society of Radiology.
Copyright_xml – notice: European Society of Radiology 2021
– notice: European Society of Radiology 2021.
– notice: 2021. European Society of Radiology.
DBID AAYXX
CITATION
NPM
3V.
7QO
7RV
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7P
NAPCQ
P5Z
P62
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
7X8
DOI 10.1007/s00330-021-07729-9
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Nursing & Allied Health Premium
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest Central Student
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Advanced Technologies & Aerospace Database
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Central Student

MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-1084
EndPage 8661
ExternalDocumentID 33895858
10_1007_s00330_021_07729_9
Genre Journal Article
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
04C
06C
06D
0R~
0VY
1N0
1SB
2.D
203
28-
29G
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
67Z
6NX
6PF
7RV
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFO
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADOJX
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEAQA
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFJLC
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARAPS
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBNVY
BBWZM
BDATZ
BENPR
BGLVJ
BGNMA
BHPHI
BKEYQ
BMSDO
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
ECF
ECT
EIHBH
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HCIFZ
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I-F
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LK8
LLZTM
M1P
M4Y
M7P
MA-
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P62
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UDS
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
WOW
YLTOR
Z45
Z7R
Z7U
Z7X
Z7Y
Z7Z
Z82
Z83
Z85
Z87
Z88
Z8M
Z8O
Z8R
Z8S
Z8T
Z8V
Z8W
Z8Z
Z91
Z92
ZMTXR
ZOVNA
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
ADHKG
ADKFA
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
NPM
7QO
7XB
8FD
8FK
ABRTQ
AZQEC
DWQXO
FR3
GNUQQ
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
7X8
ID FETCH-LOGICAL-c375t-3bedee56795461d4cd48e21ec50bfd7224a0d300b58aca612d38581504e6c7cd3
IEDL.DBID U2A
ISSN 0938-7994
1432-1084
IngestDate Fri Sep 05 07:20:05 EDT 2025
Fri Jul 25 19:06:03 EDT 2025
Thu Apr 03 07:09:50 EDT 2025
Tue Jul 01 03:08:24 EDT 2025
Thu Apr 24 23:02:35 EDT 2025
Fri Feb 21 02:47:36 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Retrospective studies
Propensity score
Humans
Liver neoplasms
Ablation techniques
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-3bedee56795461d4cd48e21ec50bfd7224a0d300b58aca612d38581504e6c7cd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-7527-6181
PMID 33895858
PQID 2582892932
PQPubID 54162
PageCount 13
ParticipantIDs proquest_miscellaneous_2518741230
proquest_journals_2582892932
pubmed_primary_33895858
crossref_citationtrail_10_1007_s00330_021_07729_9
crossref_primary_10_1007_s00330_021_07729_9
springer_journals_10_1007_s00330_021_07729_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-11-01
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-01
  day: 01
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle European radiology
PublicationTitleAbbrev Eur Radiol
PublicationTitleAlternate Eur Radiol
PublicationYear 2021
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Peng, Zhang, Chen (CR8) 2008; 17
Huang, Yu, Liang (CR41) 2014; 83
Wang, Sofocleous, Erinjeri (CR29) 2013; 36
Marrero, Kulik, Sirlin (CR3) 2018; 68
Lonjon, Porcher, Ergina, Fouet, Boutron (CR39) 2017; 265
Brace, Sampson, Hinshaw, Sandhu, Lee (CR15) 2009; 20
Omata, Cheng, Kokudo (CR1) 2017; 11
Zhang, Liang, Chen (CR10) 2007; 244
Kamal, Elmoety, Rostom, Shater, Lashen (CR35) 2019; 10
Lee, Lee, Yoon (CR20) 2012; 13
CR34
Peng, Zhang, Chen (CR11) 2013; 31
Morimoto, Numata, Kondou, Nozaki, Morita, Tanaka (CR38) 2010; 116
Sun, Cheng, Wu (CR32) 2015; 21
Teratani, Yoshida, Shiina (CR5) 2006; 43
Vietti Violi, Duran, Guiu (CR36) 2018; 3
Park, Kim, Rhim, Lim, Lee, Choi (CR13) 2011; 22
CR2
Lee, Kang, Lim (CR4) 2020; 30
Lee, Han, Kim (CR16) 2007; 42
Kim, Won, Shin (CR14) 2011; 18
Bruix, Sherman (CR21) 2005; 42
Lee, Kang, Cha (CR40) 2018; 69
Shiina, Tateishi, Arano (CR7) 2012; 107
Lee, Lee, Lee (CR31) 2014; 270
Ahmed, Solbiati, Brace (CR25) 2014; 273
Choi, Lee, Lee (CR17) 2016; 11
Teng, Liu, Lin (CR24) 2015; 4
Hocquelet, Trillaud, Frulio (CR30) 2016; 27
Loriaud, Denys, Seror (CR42) 2018; 34
Laeseke, Sampson, Haemmerich (CR23) 2006; 241
Kim, Lim, Rhim (CR6) 2013; 58
Ahmed, Solbiati, Brace (CR27) 2014; 25
Cho, Rhim, Ahn, Kim, Lim (CR12) 2006; 186
Hocquelet, Aube, Rode (CR26) 2017; 66
D’Agostino (CR28) 1998; 17
Chen, Li, Zheng (CR9) 2006; 243
Nault, Sutter, Nahon, Ganne-Carrie, Seror (CR33) 2017; 68
Laeseke, Sampson, Frey (CR22) 2007; 18
Lin, Cheng, Chen, Lin (CR18) 2016; 5
Kang, Yoon, Jeong (CR37) 2009; 20
Woo, Lee, Yoon (CR19) 2013; 268
PF Laeseke (7729_CR22) 2007; 18
7729_CR34
G Lonjon (7729_CR39) 2017; 265
DH Lee (7729_CR31) 2014; 270
PF Laeseke (7729_CR23) 2006; 241
MJ Park (7729_CR13) 2011; 22
JM Lee (7729_CR16) 2007; 42
JH Kim (7729_CR14) 2011; 18
CC Lin (7729_CR18) 2016; 5
A Hocquelet (7729_CR30) 2016; 27
S Shiina (7729_CR7) 2012; 107
A Kamal (7729_CR35) 2019; 10
JC Nault (7729_CR33) 2017; 68
JA Marrero (7729_CR3) 2018; 68
M Omata (7729_CR1) 2017; 11
MW Lee (7729_CR4) 2020; 30
A Hocquelet (7729_CR26) 2017; 66
W Teng (7729_CR24) 2015; 4
J Lee (7729_CR20) 2012; 13
J Bruix (7729_CR21) 2005; 42
M Ahmed (7729_CR25) 2014; 273
S Huang (7729_CR41) 2014; 83
A Loriaud (7729_CR42) 2018; 34
ZW Peng (7729_CR8) 2008; 17
M Morimoto (7729_CR38) 2010; 116
YK Cho (7729_CR12) 2006; 186
M Ahmed (7729_CR27) 2014; 25
AX Sun (7729_CR32) 2015; 21
MS Chen (7729_CR9) 2006; 243
YJ Zhang (7729_CR10) 2007; 244
RB D’Agostino Jr (7729_CR28) 1998; 17
X Wang (7729_CR29) 2013; 36
JW Choi (7729_CR17) 2016; 11
YS Kim (7729_CR6) 2013; 58
7729_CR2
ZW Peng (7729_CR11) 2013; 31
SG Kang (7729_CR37) 2009; 20
S Lee (7729_CR40) 2018; 69
T Teratani (7729_CR5) 2006; 43
S Woo (7729_CR19) 2013; 268
CL Brace (7729_CR15) 2009; 20
N Vietti Violi (7729_CR36) 2018; 3
References_xml – volume: 11
  start-page: e0161980
  year: 2016
  ident: CR17
  article-title: Switching monopolar radiofrequency ablation using a separable cluster electrode in patients with hepatocellular carcinoma: a prospective study
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0161980
– volume: 270
  start-page: 900
  year: 2014
  end-page: 909
  ident: CR31
  article-title: Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis
  publication-title: Radiology
  doi: 10.1148/radiol.13130940
– volume: 241
  start-page: 116
  year: 2006
  end-page: 124
  ident: CR23
  article-title: Multiple-electrode radiofrequency ablation creates confluent areas of necrosis: in vivo porcine liver results
  publication-title: Radiology
  doi: 10.1148/radiol.2411051271
– volume: 22
  start-page: 771
  year: 2011
  end-page: 779
  ident: CR13
  article-title: A comparison of US-guided percutaneous radiofrequency ablation of medium-sized hepatocellular carcinoma with a cluster electrode or a single electrode with a multiple overlapping ablation technique
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2011.02.005
– volume: 4
  start-page: 26
  year: 2015
  end-page: 38
  ident: CR24
  article-title: Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation
  publication-title: Liver Cancer
  doi: 10.1159/000343877
– volume: 243
  start-page: 321
  year: 2006
  end-page: 328
  ident: CR9
  article-title: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma
  publication-title: Ann Surg
  doi: 10.1097/01.sla.0000201480.65519.b8
– ident: CR2
– volume: 25
  start-page: 1691
  year: 2014
  end-page: 1705 e1694
  ident: CR27
  article-title: Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2014.08.027
– volume: 3
  start-page: 317
  year: 2018
  end-page: 325
  ident: CR36
  article-title: Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(18)30029-3
– volume: 42
  start-page: 1208
  year: 2005
  end-page: 1236
  ident: CR21
  article-title: Management of hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.20933
– volume: 42
  start-page: 676
  year: 2007
  end-page: 683
  ident: CR16
  article-title: Multiple-electrode radiofrequency ablation of in vivo porcine liver: comparative studies of consecutive monopolar, switching monopolar versus multipolar modes
  publication-title: Invest Radiol
  doi: 10.1097/RLI.0b013e3180661aad
– volume: 36
  start-page: 166
  year: 2013
  end-page: 175
  ident: CR29
  article-title: Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases
  publication-title: Cardiovasc Intervent Radiol
  doi: 10.1007/s00270-012-0377-1
– volume: 27
  start-page: 1038
  year: 2016
  end-page: 1045 e1032
  ident: CR30
  article-title: Three-dimensional measurement of hepatocellular carcinoma ablation zones and margins for predicting local tumor progression
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2016.02.031
– volume: 18
  start-page: 1005
  year: 2007
  end-page: 1010
  ident: CR22
  article-title: Multiple-electrode radiofrequency ablation: comparison with a conventional cluster electrode in an in vivo porcine kidney model
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2007.05.010
– volume: 21
  start-page: 2997
  year: 2015
  end-page: 3004
  ident: CR32
  article-title: Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v21.i10.2997
– volume: 30
  start-page: 2391
  year: 2020
  end-page: 2400
  ident: CR4
  article-title: Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival
  publication-title: Eur Radiol
  doi: 10.1007/s00330-019-06575-0
– volume: 58
  start-page: 89
  year: 2013
  end-page: 97
  ident: CR6
  article-title: Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2012.09.020
– volume: 273
  start-page: 241
  year: 2014
  end-page: 260
  ident: CR25
  article-title: Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update
  publication-title: Radiology
  doi: 10.1148/radiol.14132958
– volume: 43
  start-page: 1101
  year: 2006
  end-page: 1108
  ident: CR5
  article-title: Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations
  publication-title: Hepatology
  doi: 10.1002/hep.21164
– volume: 31
  start-page: 426
  year: 2013
  end-page: 432
  ident: CR11
  article-title: Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.42.9936
– volume: 20
  start-page: 118
  year: 2009
  end-page: 124
  ident: CR15
  article-title: Radiofrequency ablation: simultaneous application of multiple electrodes via switching creates larger, more confluent ablations than sequential application in a large animal model
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2008.09.021
– volume: 186
  start-page: S269
  year: 2006
  end-page: S274
  ident: CR12
  article-title: Percutaneous radiofrequency ablation therapy of hepatocellular carcinoma using multitined expandable electrodes: comparison of subcapsular and nonsubcapsular tumors
  publication-title: AJR Am J Roentgenol
  doi: 10.2214/AJR.04.1346
– volume: 10
  start-page: 562
  year: 2019
  end-page: 571
  ident: CR35
  article-title: Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial
  publication-title: J Gastrointest Oncol
  doi: 10.21037/jgo.2019.01.34
– volume: 5
  start-page: 8
  year: 2016
  end-page: 20
  ident: CR18
  article-title: The effectiveness of multiple electrode radiofrequency ablation in patients with hepatocellular carcinoma with lesions more than 3 cm in size and Barcelona Clinic Liver Cancer stage A to B2
  publication-title: Liver Cancer
  doi: 10.1159/000367755
– volume: 107
  start-page: 569
  year: 2012
  end-page: 577
  ident: CR7
  article-title: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2011.425
– volume: 20
  start-page: 1570
  year: 2009
  end-page: 1577
  ident: CR37
  article-title: Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2009.09.003
– volume: 34
  start-page: 1171
  year: 2018
  end-page: 1178
  ident: CR42
  article-title: Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems
  publication-title: Int J Hyperthermia
  doi: 10.1080/02656736.2018.1440017
– volume: 116
  start-page: 5452
  year: 2010
  end-page: 5460
  ident: CR38
  article-title: Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization
  publication-title: Cancer
  doi: 10.1002/cncr.25314
– volume: 66
  start-page: 67
  year: 2017
  end-page: 74
  ident: CR26
  article-title: Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2016.07.010
– volume: 244
  start-page: 599
  year: 2007
  end-page: 607
  ident: CR10
  article-title: Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial
  publication-title: Radiology
  doi: 10.1148/radiol.2442060826
– volume: 13
  start-page: 34
  year: 2012
  end-page: 43
  ident: CR20
  article-title: Percutaneous radiofrequency ablation with multiple electrodes for medium-sized hepatocellular carcinomas
  publication-title: Korean J Radiol
  doi: 10.3348/kjr.2012.13.1.34
– ident: CR34
– volume: 18
  start-page: 1624
  year: 2011
  end-page: 1629
  ident: CR14
  article-title: Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-011-1673-8
– volume: 268
  start-page: 589
  year: 2013
  end-page: 600
  ident: CR19
  article-title: Small- and medium-sized hepatocellular carcinomas: monopolar radiofrequency ablation with a multiple-electrode switching system-mid-term results
  publication-title: Radiology
  doi: 10.1148/radiol.13121736
– volume: 17
  start-page: 2265
  year: 1998
  end-page: 2281
  ident: CR28
  article-title: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group
  publication-title: Stat Med
  doi: 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
– volume: 83
  start-page: 552
  year: 2014
  end-page: 558
  ident: CR41
  article-title: Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: a long-term follow-up
  publication-title: Eur J Radiol
  doi: 10.1016/j.ejrad.2013.12.015
– volume: 68
  start-page: 723
  year: 2018
  end-page: 750
  ident: CR3
  article-title: Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
  publication-title: Hepatology
  doi: 10.1002/hep.29913
– volume: 17
  start-page: 23
  year: 2008
  end-page: 31
  ident: CR8
  article-title: Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma
  publication-title: Surg Oncol
  doi: 10.1016/j.suronc.2007.08.002
– volume: 11
  start-page: 317
  year: 2017
  end-page: 370
  ident: CR1
  article-title: Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
  publication-title: Hepatol Int
  doi: 10.1007/s12072-017-9799-9
– volume: 265
  start-page: 901
  year: 2017
  end-page: 909
  ident: CR39
  article-title: Potential pitfalls of reporting and bias in observational studies with propensity score analysis assessing a surgical procedure: a methodological systematic review
  publication-title: Ann Surg
  doi: 10.1097/SLA.0000000000001797
– volume: 69
  start-page: 70
  year: 2018
  end-page: 78
  ident: CR40
  article-title: Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.02.026
– volume: 68
  start-page: 783
  year: 2017
  end-page: 797
  ident: CR33
  article-title: Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.10.004
– volume: 11
  start-page: e0161980
  year: 2016
  ident: 7729_CR17
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0161980
– volume: 3
  start-page: 317
  year: 2018
  ident: 7729_CR36
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(18)30029-3
– volume: 20
  start-page: 1570
  year: 2009
  ident: 7729_CR37
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2009.09.003
– volume: 83
  start-page: 552
  year: 2014
  ident: 7729_CR41
  publication-title: Eur J Radiol
  doi: 10.1016/j.ejrad.2013.12.015
– volume: 243
  start-page: 321
  year: 2006
  ident: 7729_CR9
  publication-title: Ann Surg
  doi: 10.1097/01.sla.0000201480.65519.b8
– volume: 58
  start-page: 89
  year: 2013
  ident: 7729_CR6
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2012.09.020
– volume: 265
  start-page: 901
  year: 2017
  ident: 7729_CR39
  publication-title: Ann Surg
  doi: 10.1097/SLA.0000000000001797
– volume: 34
  start-page: 1171
  year: 2018
  ident: 7729_CR42
  publication-title: Int J Hyperthermia
  doi: 10.1080/02656736.2018.1440017
– volume: 244
  start-page: 599
  year: 2007
  ident: 7729_CR10
  publication-title: Radiology
  doi: 10.1148/radiol.2442060826
– volume: 18
  start-page: 1624
  year: 2011
  ident: 7729_CR14
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-011-1673-8
– volume: 273
  start-page: 241
  year: 2014
  ident: 7729_CR25
  publication-title: Radiology
  doi: 10.1148/radiol.14132958
– volume: 27
  start-page: 1038
  year: 2016
  ident: 7729_CR30
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2016.02.031
– volume: 186
  start-page: S269
  year: 2006
  ident: 7729_CR12
  publication-title: AJR Am J Roentgenol
  doi: 10.2214/AJR.04.1346
– volume: 4
  start-page: 26
  year: 2015
  ident: 7729_CR24
  publication-title: Liver Cancer
  doi: 10.1159/000343877
– volume: 68
  start-page: 783
  year: 2017
  ident: 7729_CR33
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.10.004
– volume: 20
  start-page: 118
  year: 2009
  ident: 7729_CR15
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2008.09.021
– volume: 68
  start-page: 723
  year: 2018
  ident: 7729_CR3
  publication-title: Hepatology
  doi: 10.1002/hep.29913
– volume: 43
  start-page: 1101
  year: 2006
  ident: 7729_CR5
  publication-title: Hepatology
  doi: 10.1002/hep.21164
– volume: 241
  start-page: 116
  year: 2006
  ident: 7729_CR23
  publication-title: Radiology
  doi: 10.1148/radiol.2411051271
– volume: 66
  start-page: 67
  year: 2017
  ident: 7729_CR26
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2016.07.010
– volume: 25
  start-page: 1691
  year: 2014
  ident: 7729_CR27
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2014.08.027
– volume: 30
  start-page: 2391
  year: 2020
  ident: 7729_CR4
  publication-title: Eur Radiol
  doi: 10.1007/s00330-019-06575-0
– volume: 17
  start-page: 23
  year: 2008
  ident: 7729_CR8
  publication-title: Surg Oncol
  doi: 10.1016/j.suronc.2007.08.002
– ident: 7729_CR34
  doi: 10.1016/j.hpb.2020.01.008
– volume: 116
  start-page: 5452
  year: 2010
  ident: 7729_CR38
  publication-title: Cancer
  doi: 10.1002/cncr.25314
– volume: 42
  start-page: 676
  year: 2007
  ident: 7729_CR16
  publication-title: Invest Radiol
  doi: 10.1097/RLI.0b013e3180661aad
– volume: 13
  start-page: 34
  year: 2012
  ident: 7729_CR20
  publication-title: Korean J Radiol
  doi: 10.3348/kjr.2012.13.1.34
– volume: 268
  start-page: 589
  year: 2013
  ident: 7729_CR19
  publication-title: Radiology
  doi: 10.1148/radiol.13121736
– volume: 270
  start-page: 900
  year: 2014
  ident: 7729_CR31
  publication-title: Radiology
  doi: 10.1148/radiol.13130940
– volume: 22
  start-page: 771
  year: 2011
  ident: 7729_CR13
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2011.02.005
– volume: 69
  start-page: 70
  year: 2018
  ident: 7729_CR40
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.02.026
– volume: 21
  start-page: 2997
  year: 2015
  ident: 7729_CR32
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v21.i10.2997
– volume: 10
  start-page: 562
  year: 2019
  ident: 7729_CR35
  publication-title: J Gastrointest Oncol
  doi: 10.21037/jgo.2019.01.34
– volume: 11
  start-page: 317
  year: 2017
  ident: 7729_CR1
  publication-title: Hepatol Int
  doi: 10.1007/s12072-017-9799-9
– volume: 42
  start-page: 1208
  year: 2005
  ident: 7729_CR21
  publication-title: Hepatology
  doi: 10.1002/hep.20933
– volume: 18
  start-page: 1005
  year: 2007
  ident: 7729_CR22
  publication-title: J Vasc Interv Radiol
  doi: 10.1016/j.jvir.2007.05.010
– volume: 17
  start-page: 2265
  year: 1998
  ident: 7729_CR28
  publication-title: Stat Med
  doi: 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
– volume: 31
  start-page: 426
  year: 2013
  ident: 7729_CR11
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.42.9936
– volume: 107
  start-page: 569
  year: 2012
  ident: 7729_CR7
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2011.425
– ident: 7729_CR2
  doi: 10.1016/j.jhep.2018.03.019
– volume: 5
  start-page: 8
  year: 2016
  ident: 7729_CR18
  publication-title: Liver Cancer
  doi: 10.1159/000367755
– volume: 36
  start-page: 166
  year: 2013
  ident: 7729_CR29
  publication-title: Cardiovasc Intervent Radiol
  doi: 10.1007/s00270-012-0377-1
SSID ssj0009147
Score 2.3682847
Snippet Objectives Radiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the...
Radiofrequency ablation (RFA) of medium-sized (3-5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the ablative...
ObjectivesRadiofrequency ablation (RFA) of medium-sized (3–5 cm) hepatocellular carcinoma (HCC) is suboptimal. Switching monopolar RFA (SW-RFA) enlarges the...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 8649
SubjectTerms Ablation
Coagulation
Confidence intervals
Diagnostic Radiology
Failure rates
Hepatobiliary-Pancreas
Hepatocellular carcinoma
Imaging
Internal Medicine
Interventional Radiology
Liver cancer
Medicine
Medicine & Public Health
Neuroradiology
Patients
Progressions
Radio frequency
Radiofrequency ablation
Radiology
Safety margins
Survival
Switching
Tumors
Ultrasound
SummonAdditionalLinks – databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLfYkKZdEB-DdRRkJG6bReLYSXxCCFEmpHGBSb1F_gpUauPSpkLjr-c9x22FJnpN7MR6z_b7fj9C3lYeW6gow4QRYKAYnjPNHR48p4xttcpiy_ybr-X1rfgyldPkcFuntMrtnRgvahcs-sjfcYzvgCwv-PvlL4aoURhdTRAaR-RhzkHWYqX45PO-6W4eAcbAaK9ZpZRIRTOxdA5BzDKGCQoZKphM_SuY7mmb9yKlUQBNHpNHSXOkHwZWPyEPfPeUnNyk2Pgzsvz2e9bHzEgKa0XsA72iK-1moV0N-dJ3VJsh9Y3Ooi_Br-k8dD8YXs80bHqgBDwKLcWI-2bB1rM_3tGfILH6gB5-TFmlFtGHurDQZ-R28un7x2uW8BSYLSrZs8J4570sKyVFmTthnag9z72VmWldBcJcZ67IMiNrbTWoPg6jhqAxCl_ayrriOTnuQufPCRWmVb6tZaudipE3ZbiS3JW1LaUs1IjkW2I2NjUbR8yLebNrkxwZ0AADmsiABuZc7uYsh1YbB0ePtzxq0rFbN_tNMiJvdq_hwCCNdOfDBscgDCEI7GxEXgy83f0O7HUF9lM9IldbZu8__v-1XBxey0tyynGjxQrGMTnuVxv_ClSZ3ryO-_UvhDbvGg
  priority: 102
  providerName: ProQuest
Title Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma
URI https://link.springer.com/article/10.1007/s00330-021-07729-9
https://www.ncbi.nlm.nih.gov/pubmed/33895858
https://www.proquest.com/docview/2582892932
https://www.proquest.com/docview/2518741230
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1ra9swUKwtjH0Z7Z7Z2qDBvm0CW5Zs62NSkpaNhrEtkH0yenkLtHZJHEb763cnP8roNtgXC2y9rDvp7nQvQt5mHkOoKMOEESCgGB4zzR1uPKeMLbWKQsj8i0V6vhQfVnLVOYVte2v3XiUZTurB2Q3TjkUMTQoiZAmZ2iMHEuNJARYv-eQu1G4c0oqBqJ6zTCnRucr8uY_fydE9HvOefjSQnfkhedzxi3TSAviIPPDVE_LwotOIPyXXX36um2APSQGhMOOB3tCNduu63LRW0jdUm9bgja7DDYLf0su6-s7wUKb1roHfh1d1SVHPvrti2_Wtd_QH0Kmmxnt9NFSlFnMOVfWVfkaW89nX03PWZVFgNslkwxLjnfcyzZQUaeyEdSL3PPZWRqZ0GZBwHbkkiozMtdXA8DjUFQKfKHxqM-uS52S_qiv_klBhSuXLXJbaqaBvU4YryV2a21TKRI1I3C9mYbsQ45jp4rIYgiMHABQAgCIAoIA274Y2122AjX_WPu5hVHSbbVvwMBXgW_iIvBk-wzbBNdKVr3dYB5MPApmORuRFC9thOJDSFUhN-Yi874F91_nf5_Lq_6q_Jo84Il7wYzwm-81m50-AoWnMmOxlqwye-fxsTA4m8-l0geXZt48zKKezxafP44DjvwB2VvJy
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiDcLBYwEJ7BIHDuJDxXi0WpLuysErdRb8CuwUpssu1lV5cfx25hxkl2hit56TWwnmodn7Hl8hLzMPLZQUYYJI-CAYnjMNHeoeE4ZW2oVhZb540k6OhKfj-XxBvnT18JgWmW_J4aN2tUW78jfcozvgC1P-LvZL4aoURhd7SE0dAet4LZDi7GusGPfn5_BEW6xvfcJ-P2K892dw48j1qEMMJtksmGJ8c57mWZKijR2wjqRex57KyNTugxMnI5cEkVG5tpqcAgcxtLAjxI-tZl1Cax7jWwKvEAZkM0PO5MvX9dtf-MAcRYp2FYypURXthOK9xBGLWKYIhGhi8vUv6bxgr97IVYbTODubXKr813p-1bY7pANX90l18dddP4emX07mzYhN5MCtRB9Qc_pXLtpXc7bjO1zqk2bfEen4TbDL-hJXf1gaCBovWyAF_CoLinG_JenbDH97R39CTazqTHGgEmz1CL-UVWf6vvk6Epo_YAMqrryjwgVplS-zGWpnQqxP2W4ktyluU2lTNSQxD0xC9u1O0fUjZNi1ag5MKAABhSBAQXMeb2aM2ubfVw6eqvnUdEp_qJYi-mQvFi9BpVFGunK10scg0CI4DJEQ_Kw5e3qcwk4kHCCy4fkTc_s9eL__5fHl__Lc3JjdDg-KA72JvtPyE2OQhfqKbfIoJkv_VNwrBrzrJNeSr5ftcL8BZYzMqw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcEG-2FDASnMBq4sRJfEAIUZaW0goJKvUW_Aqs1Cbb3ayq8tP4dcw4ya5QRW-9JrYTzcMz9jw-gJe5pxYqyvDUpHhAMSLmWjhSPKeMrbSKQsv8g8Ns9yj9fCyP1-DPUAtDaZXDnhg2atdYuiPfFhTfQVueiO2qT4v4ujN-Nz3jhCBFkdYBTqMTkX1_cY7Ht_nbvR3k9Sshxh-_f9jlPcIAt0kuW54Y77yXWa5kmsUutS4tvIi9lZGpXI7mTUcuiSIjC201OgOO4mjoQ6U-s7l1Ca57A27mCeoJVamPP60a_sYB3CxSuKHkSqV9wU4o2yMAtYhTckREzi1X_xrFS57upShtMH7jO3C791rZ-07M7sKar-_BxkEfl78P02_nkzZkZTKkDeEu6BmbaTdpqlmXq33BtOnS7tgk3GP4OTtp6p-cTANrFi1yAR81FaNo_-KUzye_vWO_0Fq2DUUXKF2WWUI-qptT_QCOroXSD2G9bmr_GFhqKuWrQlbaqRD1U0YoKVxW2EzKRI0gHohZ2r7ROeFtnJTLFs2BASUyoAwMKHHO6-Wcadfm48rRWwOPyl7l5-VKQEfwYvkalZVopGvfLGgMQSCisxCN4FHH2-XnEnQd8exWjODNwOzV4v__l82r_-U5bKCalF_2DvefwC1BMhcKKbdgvZ0t_FP0qFrzLIgugx_XrSt_AS8SMEg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Switching+monopolar+radiofrequency+ablation+improves+long-term+outcomes+of+medium-sized+hepatocellular+carcinoma&rft.jtitle=European+radiology&rft.au=Lin%2C+Chen-Chun&rft.au=Lui%2C+Kar-Wai&rft.au=Chen%2C+Wei-Ting&rft.au=Hsieh%2C+Yi-Chung&rft.date=2021-11-01&rft.issn=0938-7994&rft.eissn=1432-1084&rft.volume=31&rft.issue=11&rft.spage=8649&rft.epage=8661&rft_id=info:doi/10.1007%2Fs00330-021-07729-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00330_021_07729_9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0938-7994&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0938-7994&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0938-7994&client=summon